Immobilized Monoclonal Anti-Human CD73 Antibody, Human IgG1 at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD73, His,Avitag (Cat. No. CD3-H82E3) with a linear range of 0.6-5 ng/mL (QC tested).
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD3-H82E3 | Human | Biotinylated Human CD73 / NT5E Protein, His,Avitag™ |  |
|
|
| CD3-M52H9 | Mouse | Mouse CD73 / NT5E Protein, His Tag |  |
|
|
| CD3-H52H7 | Human | Human CD73 / NT5E Protein, His Tag (HPLC-verified) |  |
|
|
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CPI-006 | CPI-006 | Phase Ⅰ | Corvus | Triple negative breast cancer, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Endometrial cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Colorectal cancer, Metastatic castration-resistant prostate cancer (mCRPC), Sarcoma, Bladder cancer, Ovarian cancer, Cervical carcinoma, Pancreatic cancer | Details |
| Anti-CD73 monoclonal antibody (Bristol-Myers Squibb) | Phase Ⅰ | Bristol-Myers Squibb | Cancer | Details | |
| TJ-004309 | TJD-5; TJ-004309; TJ-4309 | Phase Ⅰ | I-MAB Biopharma, Tracon Pharma | Solid tumours, Metastatic cancer | Details |
| LY-3475070 | LY-3475070 | Phase Ⅰ | Lilly | Cancer | Details |
| BMS-986179 | BMS-986179 | Phase Ⅱ | Bristol-Myers Squibb | Solid tumours | Details |
| Oleclumab | MEDI-9447 | Phase Ⅱ | MedImmune | Non small cell lung cancer (NSCLC), Prostate cancer, Breast cancer, Ovarian cancer, Pancreatic cancer | Details |
| AB-680 | AB-680 | Phase Ⅰ | Arcus Biosciences | Cancer | Details |
| SRF-373 | SRF-373; NZV-930 | Phase Ⅰ | Surface Oncology, Novartis | Solid tumours | Details |
This web search service is supported by Google Inc.
A-Z